Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer
Matthias Pfeifer, Jonathan Brammeld, Stacey Price, James Pilling, Deepa Bhavsar, Anca M. Farcas, Jess Bateson, Anjana Sundarrajan, Ricardo J. Miragaia, Nin Guan, Stephanie Arnold, L. Tariq, Michael Grondine, Sarah Talbot, Maria Lisa Guerriero, Daniel O’Neill, Jamie Young, Shanade Dunn, Hannah Thorpe, Matthew J. Martin, Kimberly Maratea, Daniel Barrell, Miika Ahdesmäki, Jerome T. Mettetal, James E. Brownell, Ultan McDermott
Abstract
Most lung cancer patients with metastatic cancer eventually relapse with drug-resistant disease following treatment and EGFR mutant lung cancer is no exception. Genome-wide CRISPR screens, to either knock out or overexpress all protein-coding genes in cancer cell lines, revealed the landscape of pathways that cause resistance to the EGFR inhibitors osimertinib or gefitinib in EGFR mutant lung cancer. Among the most recurrent resistance genes were those that regulate the Hippo pathway. Following osimertinib treatment a subpopulation of cancer cells are able to survive and over time develop stable resistance. These 'persister' cells can exploit non-genetic (transcriptional) programs that enable cancer cells to survive drug treatment. Using genetic and pharmacologic tools we identified Hippo signalling as an important non-genetic mechanism of cell survival following osimertinib treatment. Further, we show that combinatorial targeting of the Hippo pathway and EGFR is highly effective in EGFR mutant lung cancer cells and patient-derived organoids, suggesting a new therapeutic strategy for EGFR mutant lung cancer patients.